The results from a clinical trial have been recently published in a preprint:
Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease. A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02) (Preprint). Figueroa et al. 2021. ( https://doi.org/10.1101/2021.04.13.21255409 ).
394 participants. 196 in the intervention arm and 198 in the placebo arm. In the placebo arm there were 10 infected persons, while in the intervention arm there were 2. However, looking at the timeline, the first of the two infected in the intervention arm was positive on day 2 since randomization, so that’s probably a case of preinfection. That would leave it as 10 vs. 1 infections. The second infection in the intervention arm seems to have occurred at day 5, just as the first one in the placebo arm. I guess it’s debatable whether those can be considered preinfections or not. However, it does leave us with 9 vs. 0 infections after day 5 and in the next 20 days in this high risk cohort. So from day 5, 100% efficacy (or from day 2, 90%?). I think this trial’s results deserve some attention.
Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease. A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02) (Preprint). Figueroa et al. 2021. ( https://doi.org/10.1101/2021.04.13.21255409 ).
394 participants. 196 in the intervention arm and 198 in the placebo arm. In the placebo arm there were 10 infected persons, while in the intervention arm there were 2. However, looking at the timeline, the first of the two infected in the intervention arm was positive on day 2 since randomization, so that’s probably a case of preinfection. That would leave it as 10 vs. 1 infections. The second infection in the intervention arm seems to have occurred at day 5, just as the first one in the placebo arm. I guess it’s debatable whether those can be considered preinfections or not. However, it does leave us with 9 vs. 0 infections after day 5 and in the next 20 days in this high risk cohort. So from day 5, 100% efficacy (or from day 2, 90%?). I think this trial’s results deserve some attention.
Media is too big
VIEW IN TELEGRAM
G. Edward Griffin "Communist Takeover" (1969 Lecture)
https://www.sciencedirect.com/science/article/pii/S1473309921004850
The negative French Randomized Controlled Trial on Remdesivir (n=857)
"No clinical benefit observed from the use of remdesivir in hospitalised patients, symptomatic for more than 7 days, on oxygen support."
The negative French Randomized Controlled Trial on Remdesivir (n=857)
"No clinical benefit observed from the use of remdesivir in hospitalised patients, symptomatic for more than 7 days, on oxygen support."